NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT04512430 2025-04-02Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsFundación GECPPhase 2 Terminated4 enrolled 9 charts